Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of ethyl icosapentate in Chinese patients with severe hypertriglyceridemia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Placebo Placebo, orally, twice daily after breakfast and dinner for 12 weeks. |
Drug: Placebo
Placebo
|
| Experimental: Ethyl Icosapentate 1.8g Ethyl Icosapentate 0.9g, orally, twice daily after breakfast and dinner for 12 weeks. |
Drug: Ethyl Icosapentate
Ethyl Icosapentate
|
| Experimental: Ethyl Icosapentate 3.6g Ethyl Icosapentate 1.8g, orally, twice daily after breakfast and dinner for 12 weeks. |
Drug: Ethyl Icosapentate
Ethyl Icosapentate
|
Outcome Measures
Primary Outcome Measures
- Percentage of change from baseline in serum triglyceride level at 12 weeks after the start of study drug administration [Baseline and 12 weeks]
- Adverse events after the start of study drug administration [12 weeks]
Secondary Outcome Measures
- Percentage of change from baseline in serum total cholesterol level at 12 weeks after the start of study drug administration [Baseline and 12 weeks]
- Percentage of change from baseline in serum low-density lipoprotein cholesterol (LDL-C) level at 12 weeks after the start of study drug administration [Baseline and 12 weeks]
- Percentage of change from baseline in serum high-density lipoprotein cholesterol (HDL-C) level at 12 weeks after the start of study drug administration [Baseline and 12 weeks]
- Adverse drug reaction after the start of study drug administration [12 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria
-
Patients whose serum Triglyceride (TG) level (fasting) from week -6 to week -4 is 500 mg/dL or higher and less than 2,000 mg/dL
-
Patients who receive instructions for lifestyle improvement and are able to comply with all instructions throughout the study participation period
-
Patients who are 18 to < 75 years of age, regardless of sex, at the time of informed consent
-
Patients who have provided written consent to participate in this clinical trial
-
Patients whose serum TG level (fasting) is less than 2,000 mg/dL at Week -2
-
Patients whose serum TG level (fasting) is less than 2,000 mg/dL at Week -1
-
Patients in whom the average of Week -2 and Week -1 in serum TG level (fasting) is 500 mg/dL or higher and less than 2,000 mg/dL
-
Outpatients
Exclusion Criteria:
-
Patients whose HbA1c from week -6 to week -4 is 8.0% or higher
-
Patients whose Alanine Aminotransferase (ALT) or Aspartate aminotransferase (AST) from week -6 to week -4 is more than 3 times the upper limit of normal
-
Patients with, or with a history of, angina pectoris or myocardial infarction
-
Patients with a history of percutaneous transluminal coronary angioplasty or coronary artery bypass grafting
-
Patients with familial lipoprotein lipase (LPL) deficiency, familial apolipoprotein C-II (apo C-II) deficiency, or familial type III, IV hyperlipidemia
-
Patients with hypothyroidism, Cushing's syndrome, acromegaly, nephrotic syndrome, chronic renal failure, systemic lupus erythematosus, myeloma, or nonalcoholic steatohepatitis (NASH)
-
Patients with hyperlipidemia induced by drugs (e.g., corticosteroids, beta-blockers, contraceptives, interferons, retinoids, and diuretics)
-
Patients with, or with a history of, alcohol dependence or abuse or patients whose hyperlipidemia is presumed to be primarily caused by alcohol
-
Patients with aortic aneurysm or who have undergone aortic aneurysmectomy within the last 6 months
-
Patients with uncontrollable hypertension (patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of ≥110 mmHg in a sitting position at Visit 1 (Week -4))
-
Patients with, or with a history of, pancreatitis or patients suspected as pancreatitis by examination, etc
-
Patients with a diagnosis of complication of pancreas or bile duct-related neoplastic disease
-
Patients with type 1 diabetes mellitus or type 2 diabetes mellitus requiring insulin therapy
-
Patients with any of the following hemorrhagic findings within the last 6 months:
-
Patients with, or with a history of, clinically significant hemorrhagic disease (e.g., cerebral hemorrhage, hemophilia, capillary fragility, gastrointestinal [GI] ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage)
-
Patients with clinically significant bleeding tendency (e.g., menorrhagia, frequent epistaxis)
-
Patients with, or with a history of, severe trauma
-
Patients with a history of surgery requiring blood transfusion
-
Patients who have taken any EPA product
-
Patients who have received a PCSK9 (human proprotein convertase subtilisin/kexin type
- inhibitor to treat hyperlipidemia
-
Patients who have taken antihyperlipidemic drugs within the last 4 weeks
-
Pregnant, possibly pregnant, or lactating women
-
Patients with a history of hypersensitivity to polyunsaturated fatty acids or gelatin
-
Patients with, or with a history of, malignant tumor
-
Patients with any serious disease, including hepatic, renal, hematologic, respiratory, GI, cardiovascular, psychological, neurologic, metabolic, and electrolyte disorders, or hypersensitivity
-
Patients who have received any other investigational drug within the last 3 months
-
Patients who are judged by the principal (or sub-) investigator to be ineligible as a study subject for any other reason
-
Patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of ≥110 mmHg at Visit 2 (Week -2))
-
Patients who have changed the dosage of antidiabetic drug (except insulin) or who have switched from one drug to another since Visit 1 (Week -4)
-
Patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of ≥110 mmHg at Visit 3 (Week -1)
-
Patients with an HbA1c level of ≥8.0% at Visit 2 (Week -2)
-
Patients whose ALT or AST is more than 3 times the upper limit of normal at Visit 2 (Week -2)
-
Patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of ≥110 mmHg at Visit 4 (Week 0)
-
Patients with an HbA1c level of ≥8.0% at Visit 3 (Week -1)
-
Patients whose ALT or AST is more than 3 times the upper limit of normal at Visit 3 (Week -1)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mochida Investigational sites | Changsha | China |
Sponsors and Collaborators
- Mochida Pharmaceutical Company, Ltd.
- Sumitomo Pharma (Suzhou) Co., Ltd.
Investigators
- Study Director: Takuya Mori, Mochida Pharmaceutical Company, Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MND2112H33
- 20191474